0001493152-26-022743
SEC filingRevenue exploded 1768% to $786K from new streams including Yerbae Brands sales, driving gross profit to $3.6M with 457% margin, though net loss of $1.8M and cash burn persisted amid expansion costs and digital asset volatility.
Despite revenue and gross profit gains, net income remained negative at -$1.8M, an improvement of 65.7% from the prior year's -$5.3M loss. Diluted EPS reflected heightened per-share pressure at -$0.23, down 187.5% from -$0.08, underscoring the impact of loss magnitude on diluted shares. These dynamics highlight operating discipline amid expansion, where research and development efforts focus on developing new therapeutic products and enhancing existing ones to address customer demands and emerging trends. All R&D costs, both internal and third-party, are expensed as incurred per ASC 730-10, contributing to the predictable treatment of these investments in the P&L.
Looking forward, management flags significant costs tied to expansion and development plans, with expectations—though no assurances—for warrant exercises to provide liquidity. Fair value of financial instruments approximates carrying amounts due to their short-term nature under ASC 820. These factors frame BNKK's trajectory: robust top-line validation from new partnerships like Yerbae, paired with disciplined cost management, positions the company for growth, but sustained losses and cash needs emphasize execution risks in a competitive landscape.